Drug
SC Methylnaltrexone (MNTX)
SC Methylnaltrexone (MNTX) is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
3
75%
Ph phase_3
1
25%
Phase Distribution
3
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 13 (75.0%)
Phase 31 (25.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_1
Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose
NCT01367496
completedphase_3
Open-Label Treatment Extension of Protocol MNTX 301
NCT01367600
completedphase_1
Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function
NCT01367522
completedphase_1
Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan
NCT01367535
Clinical Trials (4)
Showing 4 of 4 trials
NCT01367496Phase 1
Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose
NCT01367600Phase 3
Open-Label Treatment Extension of Protocol MNTX 301
NCT01367522Phase 1
Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function
NCT01367535Phase 1
Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4